Reviewing BioCryst Pharmaceuticals (BCRX) & Its Competitors

BioCryst Pharmaceuticals (NASDAQ:BCRX) is one of 844 publicly-traded companies in the “Biotechnology” industry, but how does it contrast to its rivals? We will compare BioCryst Pharmaceuticals to similar businesses based on the strength of its profitability, valuation, earnings, institutional ownership, analyst recommendations, dividends and risk.

Risk & Volatility

BioCryst Pharmaceuticals has a beta of 0.55, meaning that its share price is 45% less volatile than the S&P 500. Comparatively, BioCryst Pharmaceuticals’ rivals have a beta of 1.15, meaning that their average share price is 15% more volatile than the S&P 500.

Institutional and Insider Ownership

85.9% of BioCryst Pharmaceuticals shares are held by institutional investors. Comparatively, 47.9% of shares of all “Biotechnology” companies are held by institutional investors. 3.8% of BioCryst Pharmaceuticals shares are held by company insiders. Comparatively, 13.0% of shares of all “Biotechnology” companies are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Profitability

This table compares BioCryst Pharmaceuticals and its rivals’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
BioCryst Pharmaceuticals	-37.40%	-94.24%	69.12%
BioCryst Pharmaceuticals Competitors	-12,359.35%	-203.09%	-30.93%

Analyst Ratings

This is a summary of current recommendations and price targets for BioCryst Pharmaceuticals and its rivals, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BioCryst Pharmaceuticals	1	2	6	0	2.56
BioCryst Pharmaceuticals Competitors	9846	15131	45507	1589	2.54

BioCryst Pharmaceuticals currently has a consensus price target of $20.38, indicating a potential upside of 166.86%. As a group, “Biotechnology” companies have a potential upside of 98.03%. Given BioCryst Pharmaceuticals’ stronger consensus rating and higher probable upside, equities analysts clearly believe BioCryst Pharmaceuticals is more favorable than its rivals.

Earnings & Valuation

This table compares BioCryst Pharmaceuticals and its rivals top-line revenue, earnings per share and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
BioCryst Pharmaceuticals	$874.84 million	$263.86 million	-5.38
BioCryst Pharmaceuticals Competitors	$698.13 million	$10.43 million	-15.41

BioCryst Pharmaceuticals has higher revenue and earnings than its rivals. BioCryst Pharmaceuticals is trading at a higher price-to-earnings ratio than its rivals, indicating that it is currently more expensive than other companies in its industry.

Summary

BioCryst Pharmaceuticals beats its rivals on 10 of the 13 factors compared.

About BioCryst Pharmaceuticals

BioCryst Pharmaceuticals, Inc., a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema. It is also developing BCX10013, an oral factor D inhibitor for complement-mediated diseases. The company has collaborations and in-license relationships with the Torii Pharmaceutical Co., Ltd.; Seqirus UK Limited; Shionogi & Co., Ltd.; Green Cross Corporation; National Institute of Allergy and Infectious Diseases; Biomedical Advanced Research and Development Authority; the U.S. Department of Health and Human Services; and The University of Alabama at Birmingham, as well as Albert Einstein College of Medicine of Yeshiva University and Industrial Research, Ltd. BioCryst Pharmaceuticals, Inc. was founded in 1986 and is headquartered in Durham, North Carolina.